Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
Earnings and Valuation
This table compares Regulus Therapeutics and CorMedix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regulus Therapeutics | N/A | N/A | -$30.04 million | ($1.07) | -1.40 |
| CorMedix | $60,000.00 | 11,124.67 | -$46.34 million | ($0.81) | -13.58 |
Regulus Therapeutics has higher earnings, but lower revenue than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Regulus Therapeutics | N/A | -53.07% | -48.58% |
| CorMedix | N/A | -79.21% | -64.68% |
Risk and Volatility
Regulus Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.
Insider & Institutional Ownership
92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations for Regulus Therapeutics and CorMedix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regulus Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
| CorMedix | 0 | 0 | 5 | 0 | 3.00 |
Regulus Therapeutics currently has a consensus price target of $10.80, suggesting a potential upside of 620.00%. CorMedix has a consensus price target of $15.20, suggesting a potential upside of 38.18%. Given Regulus Therapeutics’ higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than CorMedix.
Summary
Regulus Therapeutics beats CorMedix on 7 of the 11 factors compared between the two stocks.
About Regulus Therapeutics
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
